NATCO Pharma has informed that it enclosed the intimation under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 on the U.S. Food and Drug Administration (FDA) inspection at the API manufacturing plant located in Kothur, Hyderabad, India, from 12th November to 20th November, 2026.
The above information is a part of company’s filings submitted to BSE.